VINORELBINE PIERRE FABRE vinorelbine 50mg/5mL (as tartrate) injection vial

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)

Disponible depuis:

Pierre Fabre Australia Pty Ltd

forme pharmaceutique:

Injection, concentrated

Composition:

Excipient Ingredients: water for injections

Mode d'administration:

Intravenous

Unités en paquet:

1 x 5mL, 10 x 5mL

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Vinorelbine Pierre Fabre is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. Vinorelbine Pierre Fabre is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.

Descriptif du produit:

Visual Identification: A clear, colourless to pale yellow solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2000-08-04